Inflammatory bowel disease is a serious condition characterized by chronic inflammation of the gut. Disease ranges from moderate to severe, and can greatly impact the quality of life of affected individuals. Since there is no cure, current treatments such as medications focus mainly on managing symptoms. These treatments can have adverse side effects, and may not always be fully effective. Considering this, targeted administration of anti-inflammatory agents at the disease site offers an alternate approach that may be effective in treating this disease. We propose development of an in-situ drug delivery system consisting of probiotic strains engineered to secrete anti-inflammatory compounds in response to inflammation. By utilizing an inflammatory biomarker to activate a genetic circuit within the probiotic, anti-inflammatories would only be released in the presence of active disease, preventing excessive dosage. For the probiotic, we selected E. coli Nissle 1917, which has been shown in previous studies to have innate use in treating inflammatory bowel disease. We selected nitric oxide since it is produced during gut inflammation at a sufficient concentration to function as a biomarker. For anti-inflammatory agents, we selected the small molecule tryptophan derivatives tryptamine and 1-acetyl-3-carboxyl-β-carboline, as well as the cytokine interleukin 10. In this study we seek to design and establish the effectivity of a probiotic drug delivery system to treat inflammatory bowel disease. The nitric oxide circuit displays stability in simulated intestinal and colonic fluid, highlighting its usefulness in our probiotic strains. When engineered with small molecule anti-inflammatory production in the circuit as well, the strains continue to perform well in simulated gut media, showing scaling production in response to varying nitric oxide levels. In a murine macrophage model involving Lipopolysaccharide challenged RAW264.7 cells, our engineered strains are shown to reduce inflammation levels down to the negative control.